

Contents

Contributors	v
Preface	xiii
Acknowledgments	xvii

CHAPTER 1	Sleep deprivation exacerbates concussive head injury induced brain pathology: Neuroprotective effects of nanowired delivery of cerebrolysin with α-melanocyte-stimulating hormone	1
	Aruna Sharma, Dafin F. Muresanu, Asya Ozkizilcik, Z. Ryan Tian, José Vicente Lafuente, Igor Manzhulo, Herbert Mössler, and Hari Shanker Sharma	
1.	Introduction	2
1.1.	Sleep deprivation and neurological diseases	4
1.2.	Sleep disturbances and traumatic brain injuries	7
2.	α -Melanocyte stimulating hormone (α -MSH) and CNS functions	9
2.1.	α -MSH in traumatic brain injury	9
2.2.	α -MSH therapy is neuroprotective in traumatic brain injuries	11
2.3.	α -MSH in sleep disturbances	11
3.	Neurotrophins and sleep disturbances and traumatic brain injuries	12
3.1.	Neurotrophins and sleep processes	12
3.2.	Neurotrophins and traumatic brain injury	13
4.	Cerebrolysin and traumatic brain injuries	15
4.1.	Cerebrolysin and preclinical studies on TBI	15
4.2.	Cerebrolysin in clinical TBI	15
5.	Nanodelivery of drugs induce superior neuroprotection	16
6.	Our own investigations on SD and TBI	16
6.1.	Methodological consideration	17
6.2.	Parameters measured	17
6.3.	Biochemical measurements	19
6.4.	Novel therapeutic strategies	20
7.	Sleep deprivation exacerbates concussive head injury induced brain pathology	22
7.1.	SD exacerbates blood-brain barrier breakdown in CHI	22
7.2.	SD exacerbates brain edema formation and volume swelling in CHI	24

7.3. SD exacerbates CHI induced reductions in BDNF and α -MSH levels.....	24
7.4. SD exacerbates neuronal, glial and axonal pathology in CHI.....	26
8. Cerebrolysin and α -MSH induce neuroprotection in SD after CHI.....	30
8.1. Nanodelivery of cerebrolysin and α -MSH induce superior neuroprotection.....	32
9. Possible pathophysiological mechanisms and neuroprotection.....	32
9.1. Functional significance of our findings.....	34
10. Conclusions and future perspectives.....	34
Acknowledgments.....	34
References.....	35

CHAPTER 2 Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy..... 57

Giovanni Tosi, Francesca Pederzoli, Daniela Belletti, Maria Angela Vandelli, Flavio Forni, Jason Thomas Duskey, and Barbara Ruozzi

1. Introduction.....	58
2. Technologies for brain targeting and blood-brain barrier crossing.....	60
3. Dual targeting strategy: How to cross the BBB and reach AB...66	
4. Nanocarriers as nanodrug.....	76
4.1. Exploration of A β -binding nanostructures.....	76
4.2. "Sink effect".....	78
5. Conclusion.....	80
Acknowledgments.....	81
References.....	81

CHAPTER 3 Nanowired delivery of DL-3-*n*-butylphthalide induces superior neuroprotection in concussive head injury..... 89

Feng Niu, Aruna Sharma, Lianyuan Feng, Asya Ozkizilcik, Dafin F. Muresanu, José Vicente Lafuente, Z. Ryan Tian, Ala Nozari, and Hari Shanker Sharma

1. Introduction.....	90
2. NBP is neuroprotective in brain diseases.....	91
2.1. NBP in ischemic stroke.....	92
2.2. NBP in Alzheimer's disease.....	93
2.3. NBP in Parkinson's disease.....	94
2.4. NBP in traumatic brain injury.....	94

3. Our own studies on NBP in concussive head injury	94
3.1. Methodological considerations	95
4. Parameters measured	96
4.1. Blood-brain barrier permeability	96
4.2. Brain edema formation and volume swelling	97
4.3. Neuropathology	97
5. Our observations on NBP induced neuroprotection in CHI	98
5.1. NBP reduces blood-brain barrier breakdown in CHI	98
5.2. NBP reduces edema formation and volume swelling in CHI	100
5.3. NBP reduces brain pathology	103
6. Functional significance of our findings	105
7. Conclusion and future perspectives	109
Acknowledgments	109
References	109
CHAPTER 4 Oligodendrocyte precursor cells as a therapeutic target for demyelinating diseases	119
Stephen D. Skaper	
1. Introduction	120
2. Promoting the recruitment or differentiation of OPCs as a strategy to enhance remyelination	124
2.1. Muscarinic acetylcholine receptors	124
2.2. Kappa opioid receptor	125
2.3. Histamine receptors	126
2.4. Estrogen receptor	126
2.5. Vitamin D receptor-retinoid X receptor heterodimer	127
2.6. <i>N</i> -acylethanolamines	128
3. Concluding remarks	134
References	134
Further reading	144
CHAPTER 5 Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease	145
Hari Shanker Sharma, Dafin F. Muresanu, Rudy J. Castellani, Ala Nozari, José Vicente Lafuente, Z. Ryan Tian, Asya Ozkizilcik, Igor Manzhulo, Herbert Mössler, and Aruna Sharma	
1. Introduction	146
2. Blood-brain barrier in AD pathology	148
2.1. A β P induced BBB breakdown	149
2.2. BBB disruption in AD	150

3. Plasma A β P and AD pathology	152
4. Plasma tau and AD pathology	153
5. Brain and CSF neprilysin in AD pathology	155
6. Neurotrophins and AD pathology	157
6.1. Therapeutic strategies using neurotrophins in AD	157
6.2. Cerebrolysin therapy in AD	159
7. Nanotechnology and drug delivery in AD	160
8. Our own investigations in AD pathology	160
8.1. Methodological consideration	160
8.2. Evaluation of neuroprotection in AD	161
8.3. Biochemical assay of biomarkers in AD	164
9. Novel therapeutic strategies induced neuroprotection in AD	165
9.1. A β P infusion model induces AD like brain pathology	165
9.2. Cerebrolysin induced neuroprotection in AD	169
9.3. Exogenous NPL induces neuroprotection in AD	174
9.4. Tau antibodies induce neuroprotection in AD	174
9.5. Combined treatment for superior neuroprotection in AD	174
9.6. TiO ₂ -cerebrolysin potentiates NPL and p-tau antibodies induced neuroprotection in AD	176
10. Functional significance and future perspectives in AD research	176
Acknowledgments	178
References	178

CHAPTER 6 Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease	201
Asya Ozkizilcik, Aruna Sharma, José Vicente Lafuente, Dafin F. Muresanu, Rudy J. Castellani, Ala Nozari, Z. Ryan Tian, Herbert Mössler, and Hari Shanker Sharma	
1. Introduction	202
1.1. Blood-brain barrier in Parkinson's disease	203
1.2. Neurotrophic factor in PD	205
1.3. A β P and p-tau in PD	207
1.4. α -SNC in PD	209
1.5. Nitric oxide synthase in PD	210
1.6. Nanodelivery of drugs in PD	210
2. Our own investigations in PD	211
2.1. Methodological consideration	212

3. Nanodelivery of cerebrolysin induces superior neuroprotection in PD	215
3.1. Nanodelivery of cerebrolysin restores TH positive cells and DA, DOPAC and HVA levels	215
3.2. Nanodelivery of cerebrolysin reduces BBB disturbances and brain edema formation	217
3.3. Nanodelivery of cerebrolysin reduces brain pathology	220
3.4. Nanodelivery of cerebrolysin reduces alpha-synuclein levels and nNOS expression	220
3.5. Nanodelivery of cerebrolysin reduces behavioral dysfunction	224
4. Functional significance of our findings in PD	226
Acknowledgments	227
References	228

CHAPTER 7 Tellurium epigenetic transgenerational effects on behavioral expression of coping behavior in rats... 247

Silvia G. Ratti and Edgardo O. Alvarez

1. Introduction	247
2. Materials and methods	249
2.1. Animals	249
2.2. Experimental design	249
2.3. Behavioral tests	249
2.4. Experiments	252
2.5. Statistical analysis	253
2.6. Ethical care of animals	253
3. Results	254
3.1. Experiment 1	254
3.2. Experiment 2	254
3.3. Experiment 4	256
4. Discussion	256
5. Final remarks	259
Acknowledgments	259
References	259

CHAPTER 8 Nanodelivery of therapeutic agents in Parkinson's disease... 263

José Vicente Lafuente, Catalina Requejo, and Luisa Ugedo

1. Introduction	264
1.1. About Parkinson's disease	264
1.2. About therapeutic agents	265

1.3. Remarks about BBB	265
1.4. About nanodelivery	267
2. Development	268
2.1. Nanodelivery of substitutive treatments	268
2.2. Nanodelivery of restorative treatments	270
3. Summary	273
Acknowledgments	273
References	274
 CHAPTER 9 Nanoparticles and neurotoxicity: Dual response of glutamatergic receptors	 281
Ayşe Basak Engin and Atilla Engin	
1. Introduction	282
2. How nanoparticles reach brain neurons?	282
3. Dual response of NMDAR in nanoparticle-exposed neurons ...	284
4. Is microglia friend or foe in nanoparticle-neuron interactions ...	291
5. Conclusion	294
References	295